Sanofi Israel Ltd

Influenza Vaccine. B/Phuket/3073/2013 - like strain 60 mcg, A/Victoria/4897/2022 (H1N1) pdm09-like strain 60 mcg, A/Darwin/9/2021(H3N2)-like strain 60 mcg, B/Austria/1359417/2021-like strain 60 mcg.
Prefilled syr. with susp. for IM/SC inj.  1/5/10 X 0.7 ml
Admin. one dose of 0.7 ml.
Active immunisation in adults 60 years and older for the prevention of influenza according to official recomm. on influenza vacc.
C/I:Hypersens., incl. to traces such as eggs (ovalbumin, chicken proteins) and formaldehyde.

Monoclonal Antibody. Alirocumab 75 mg/ml, 150 mg/ml.
PEN/SYR.: 1,2×75,150 mg/ml
The usual init. dose is 75 mg admin. SC once every 2 wks.
Pts. requir. larger LDL-C reduction (>60%) may be started on 150 mg admin.
SC once every 2 wks.
The dose can be individual. based on pt. characteristics such as baseline
LDL-C level, goal of ther. &response. See lit.
Primary Hypercholesterolaemia (heterozygous familial &non-familial) or mixed dyslipidaemia in adults, as an adjunct to diet:
- in comb .with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the max. tolerated dose of a statin or,
- alone or in comb. with other lipid-low. therapies in pts. who are statin-intoler.
The effect of the drug on cardiovasc. morbid. and mortal. has not yet been determin.
Establ. atherosclerotic CV dis.:in adults to reduce CV risk by lowering LDL-C levels, as an adjunct to correct. of other risk factors:
- in combin. with the max. toler. dose of a statin with or w/o other lipid-lowering therap. or,
- alone or in combin. with other lipid-lowering ther. in pts who are statin-intolerant, or for whom a statin is contraind.
C/I: Hypersens.